A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus
Objectives To develop a longitudinal statistical model to indirectly estimate the comparative efficacies of two drugs, using model-based meta-analysis (MBMA). Comparison of two oral dipeptidyl peptidase (DPP)-4 inhibitors, sitagliptin and linagliptin, for type 2 diabetes mellitus (T2DM) treatment wa...
Saved in:
Main Authors: | Yan Gong, James Rogers, Christian Friedrich, Sanjay Patel, Alexander Staab, Jorge Luiz Gross, Daniel Polhamus, William Gillespie, Brigitta Ursula Monz, Silke Retlich |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2013-03-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/3/3/e001844.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Acute Kidney Injury Associated with Linagliptin
by: Deepak K. Nandikanti, et al.
Published: (2016-01-01) -
Biological Safety Studies and Simultaneous Determination of Linagliptin and Synthetic Impurities by LC-PDA
by: Raquel Balestri Heleno Ferreira, et al.
Published: (2019-01-01) -
Deciphering the Topology of Sitagliptin Using an Integrated Approach
by: Renny Mathew, et al.
Published: (2025-01-01) -
Sitagliptin: a potential drug for the treatment of COVID-19?
by: Bardaweel Sanaa K., et al.
Published: (2021-06-01) -
Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus
by: Feng Tian, et al.
Published: (2023-02-01)